# CAN SLIM Progress Board

Last updated: 2026-09-14

Frozen quantitative v1 remains research-complete but not production-ready. FWD1 and EXH2 continue unchanged. The theory-fidelity path now has frozen contracts through #45. #43 remains the current stock-level lifecycle arbiter; #44 is climax/exhaustion evidence-only; #45 adds the independent portfolio-level CAN SLIM `M` exposure action layer.

## Repository boundary for #33

**Canonical #33 implementation and P8 morphology validation live in `azharmz/ussy-oneil-patterns`.** Frozen production contract: `oneil-pattern-output-v2` with only `FLAT_BASE`, `DOUBLE_BOTTOM`, `CUP_WITHOUT_HANDLE`, and `CUP_WITH_HANDLE`. P6 advanced patterns remain excluded and frozen.

## Theory Fidelity / v2 path

| # | Workstream | Status |
|---:|---|---|
| 25 | Theory Fidelity Audit | **COMPLETE** |
| 26 | Proper-base definitions | **COMPLETE** |
| 27 | Pivot / buy-point definition | **COMPLETE** |
| 28 | Breakout + volume confirmation | **COMPLETE** |
| 29 | RS / leadership fidelity | **COMPLETE** |
| 30 | C/A/S/I/M role fidelity | **COMPLETE** |
| 31 | Sell / risk-management fidelity | **COMPLETE** |
| 32 | Theory-faithful candidate specification | **COMPLETE / FROZEN v1** |
| 33 | O'Neil Pattern Recognition Engine | **CORE COMPLETE / FROZEN — P8 CONDITIONAL PASS** |
| 34 | Theory-faithful candidate generator | **COMPLETE / FROZEN v1** |
| 35 | New-candidate validation | **COMPLETE / FROZEN — CONDITIONAL PASS** |
| 36 | Execution / entry research | **BASELINE FROZEN / DIAGNOSTIC COMPLETE / PRIMARY PERFORMANCE VALIDATION BLOCKED_ON_ELIGIBLE_POPULATION** |
| 37 | Sell / risk execution semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 38 | Technical deterioration evidence | **EVIDENCE LAYER COMPLETE / FROZEN v1** |
| 39 | Weekly aggregation / 10-week evidence | **WEEKLY AGGREGATION + 10W EVIDENCE COMPLETE / FROZEN v1** |
| 40 | Technical deterioration action semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 41 | Position lifecycle / exit arbiter | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 42 | Round-trip sell action semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 43 | Position lifecycle / exit arbiter v2 | **IMPLEMENTATION COMPLETE / FROZEN v2** |
| 44 | Climax / exhaustion evidence | **EVIDENCE LAYER COMPLETE / FROZEN v1** |
| 45 | Market exposure action semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |

## Current canonical architecture

```text
#33 Pattern
→ #34 Candidate
→ #35 Validation
→ #36 Entry
→ OPEN POSITION
→ #37 Capital Protection
   / #40 Technical Deterioration
   / #42 Round-Trip
→ #43 Stock Lifecycle Arbiter
→ CLOSED POSITION

#44 Climax/Exhaustion = evidence sidecar only

General market / CAN SLIM M
→ upstream market-state evidence/classification [separate]
→ #45 Portfolio Exposure Action
→ target exposure band E0..E4
```

## #34–#35 candidate and validation state

Frozen candidate stages: `BASE_RECOGNIZED → PIVOT_DEFINED → PIVOT_CROSSED → BREAKOUT_CONFIRMED → CANSLIM_ELIGIBLE`.

#34 final verification `34758050282` → **SUCCESS, 9 tests**. #35 canonical historical run `34763920536` produced 265,642 observations with zero V35-A/B/C findings and a frozen 60-case corpus. Independent source-evidence audit `34765922653` → **SUCCESS**, C/A/L/M 60/60 MATCH and PIT violations = 0. #35 remains `CONDITIONAL PASS` solely with upstream #33 morphology debt preserved.

## #36–#43 stock lifecycle

#36 canonical T+1-open execution remains frozen; primary performance validation remains `BLOCKED_ON_ELIGIBLE_POPULATION` because canonical #35 has 0 `CANSLIM_ELIGIBLE` observations.

#37 capital protection, #40 technical deterioration and #42 round-trip are the three frozen executable stock-level exit channels. #43 v2 arbitrates them by earliest causal executable exit, preserving same-session ambiguity/source conflicts rather than inventing an OHLC path.

Canonical validations remain green: #36 `34785545504`; #37 `34787905360`; #38 `34788119495`; #39 `34788414986`; #40 `34789559782`; #41 `34790106465`; #42 `34793348883`; #43 `34796938374`.

## #44 — Climax / Exhaustion Evidence

Contract `44-climax-exhaustion-evidence-v1` remains evidence-only. It records reproducible climax/exhaustion channels without creating a fourth exit. Prior-advance/base-stage context remains unresolved for a canonical action rule. EXH2 remains separate and unchanged.

Canonical run `34797449482` / job `103833195506` → **SUCCESS, 10 passed in 0.03s**.

## #45 — Market Exposure Action

Specification: `docs/methodology/45-market-exposure-action-spec-v1.md`.

Contract: `45-market-exposure-action-v1`.

Frozen portfolio exposure vocabulary:

```text
E0 = 0-20%
E1 = 20-40%
E2 = 40-60%
E3 = 60-80%
E4 = 80-100%
```

Frozen action semantics:
- `CORRECTION` → E0 and block new entries;
- `RALLY_ATTEMPT` does not authorize bullish re-entry;
- `FOLLOW_THROUGH_CONFIRMED` from E0 → E1, gradual re-engagement;
- `UPTREND_HEALTHY` → at most one-band increase, capped E4;
- `UPTREND_WEAKENING` → one-band reduction, floored E0;
- `NOT_EVALUABLE` remains explicit and does not authorize new entries.

#45 is portfolio-level. It does **not** automatically liquidate every stock, choose which holding to sell, alter #36 fills, or enter #43 as a stock-level exit.

Implementation:
- `src/canslim_research/market_exposure_action_v1.py`
- `tests/test_market_exposure_action_v1.py`
- `.github/workflows/45-market-exposure-action-v1.yml`

Canonical semantic-validation run:
- run `34802432732`
- job `103847631050`
- commit `4c1f5cbf536d1d144abcd41360019dab7dfca3b8`
- **SUCCESS**
- **12 passed**

Freeze decision: `docs/decisions/2026-09-14-45-market-exposure-action-freeze.md`.

Terminal state: `IMPLEMENTATION COMPLETE / FROZEN v1`.

## Forward / production boundaries

FWD1 remains LIVE / ACCUMULATING with its existing gate; EXH2 remains separate and prospective. Production integration remains blocked by the FWD1 gate. Theory-fidelity findings must not be retrofitted into FWD1/X3/EXH2.

## Active work from here

1. Keep #33-#45 frozen.
2. Primary lifecycle/performance validation remains blocked until a genuine frozen `CANSLIM_ELIGIBLE` population exists.
3. Do not tune entry, exits, lifecycle arbitration, climax evidence, or exposure transitions from historical returns.
4. #45 still needs a separately specified **market-state evidence/classification layer** if the system is to derive `CORRECTION`, `RALLY_ATTEMPT`, `FOLLOW_THROUGH_CONFIRMED`, `UPTREND_HEALTHY`, and `UPTREND_WEAKENING` directly from index OHLCV/leadership evidence rather than consume them as inputs.
5. A future portfolio executor may translate #45 target exposure into concrete position-level actions; that must not be conflated with stock-level O'Neil sell rules.
6. A canonical climax action remains unauthorized until prior-advance/base-stage context is resolved.
7. Preserve #33 morphology debt, keep P6 out of production, and keep FWD1/EXH2 unchanged.